Taysha gene therapies to release third quarter 2022 financial results and host conference call and webcast on november 8

Dallas, nov. 02, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended september 30, 2022, and host a corporate update conference call and webcast on tuesday, november 8, 2022, at 8:00 am eastern time.
TSHA Ratings Summary
TSHA Quant Ranking